Neurotoxin treatment of the upper face

Cosmetic Dermatology

Volumn 25, Issue 9, 2012, Pages 427-432

  Trieu, Diane ^a   Ploch, Lauren Eckert ^a   Lupo, Mary P ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876225704     PISSN: 10413766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Mann D. The most common cosmetic surgery in 2011 was... Medscape News. March 20, 2012. http://www.medscape.com/viewarticle/760613. Accessed April 9, 2012.
2. Carruthers A, Carruthers J, Flynn TC, et al. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg. 2007;33(1 spec no):S60-S68.
3. Sattler G. Current and future botulinum neurotoxin type A preparations in aesthetics: a literature review. J Drugs Dermatol. 2010;9: 1065-1071.
4. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010;36(suppl 4): 2146-2154.
5. Boyer R. Cutting edge: Botox. In: Boyer R. Interactive Concepts in Biochemistry. 2nd ed. New York, NY: John Wiley & Sons; 2002. http://www.wiley.com/legacy/college/boyer/0471661791/cutting-edge/botox/botox. htm. Updated 2006. Accessed April 16, 2012.
6. Collins A, Nasir A. Topical botulinum toxin. J Clin Aesthet Dermatol. 2010;3: 35-39.
7. Tremaine AM, McCullough JL. Botulinum toxin type A for the management of glabellar rhytids. Clin Cosmet Investig Derm. 2010;3: 15-23.
8. Botox Cosmetic [package insert]. Irvine, CA: Allergan, Inc; 2011.
9. Dysport [package insert]. Scottsdale, AZ: Medicis Aesthetics Inc; 2009.
10. Xeomin [package insert]. Franksville, WI: Merz Aesthetics, Inc; 2011.
11. Carruthers A, Carruthers J. Botulinum toxin type A for the treatment of glabellar rhytides. Dermatol Clin. 2004;22: 137-144.
12. Flynn TC, Carruthers A, Carruthers J, et al. Validated assessment scales for the upper face. Dermatol Surg. 2012;38(2 spec no): 309-319.
13. Ney JP, Joseph KR. Neurologic uses of botulinum neurotoxin type A. Neuropsychiatr Dis Treat. 2007;3: 785-798.
14. Shome D, Nair AG, Kapoor R, et al. Botulinum toxin A: is it really that fragile a molecule? Dermatol Surg. 2010;36(suppl 4): 2106-2110.
15. Carruthers A, Carruthers J, Lei X, et al. OnabotulinumtoxinA treatment of mild glabellar lines in repose. Dermatol Surg. 2010;36(suppl 4): 2168-2171.
16. Prager W, Wissmüller E, Kollhorst B, et al. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg. 2010;36(suppl 4): 2155-2160.
17. Flynn TC, Carruthers JA, Carruthers JA. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg. 2001;27: 703-708.
18. Bolognia JL, Rapini R, Jorizzo JL, eds. Dermatology. 2nd ed. London, England: Mosby; 2008.
19. Mariwalla K, Leffell DJ. Primer in Dermatologic Surgery: A Study Companion. 2nd ed. Rolling Meadows, IL: American Society for Dermatologic Surgery; 2011.
20. Dressler D, Wohlfahrt K, Meyer-Rogge E, et al. Antibody-induced failure of botulinum toxin A therapy in cosmetic indications. Dermatol Surg. 2010;36(suppl 4): 2182-2187.
21. Brant F, O'Connell C, Cazzaniga A, et al. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol Surg. 2010;36(suppl 4): 2111-2118.